{
  "ticker": "ECS",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966551",
  "id": "02966551",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250707",
  "time": "0921",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljll71wkl4nj.pdf",
  "summary": "- **Clinical Trial Support**: ECS to supply Avani THC10 Softgel Capsules for a University of Western Australia study on medicinal cannabis for obstructive sleep apnoea.  \n- **Trial Focus**: Assess 10mg THC's impact on OSA severity, physiological mechanisms, and cognitive performance (24 participants, recruitment starts July 2025).  \n- **Strategic Impact**: Supports clinical validation of ECS products, reinforcing evidence-based therapeutic potential.  \n\n**No material trading or capital markets information identified.**  \n\n(Note: This is a research collaboration announcement; no financial or structural details affecting valuation/ liquidity are disclosed.)",
  "usage": {
    "prompt_tokens": 964,
    "completion_tokens": 125,
    "total_tokens": 1089,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T23:42:46.992349"
}